| Literature DB >> 28578874 |
Mohit Misra1, Maximilian Kuhn2, Mark Löbel3, Heeseon An4, Alexander V Statsyuk5, Christoph Sotriffer2, Hermann Schindelin6.
Abstract
Targeting the activating enzymes (E1) of ubiquitin (Ub) and ubiquitin-like modifiers (Ubls) has emerged as a promising anti-cancer strategy, possibly overcoming the ineffectiveness of proteasome inhibitors against solid tumors. Here, we report crystal structures of the yeast ubiquitin E1 (Uba1) with three adenosyl sulfamate inhibitors exhibiting different E1 specificities, which are all covalently linked to ubiquitin. The structures illustrate how the chemically diverse inhibitors are accommodated within the adenylation active site. When compared with the previously reported structures of various E1 enzymes, our structures provide the basis of the preferences of these inhibitors for different Ub/Ubl-activating enzymes. In vitro inhibition assays and molecular dynamics simulations validated the specificities of the inhibitors as deduced from the structures. Taken together, the structures establish a framework for the development of additional compounds targeting E1 enzymes, which will display higher potency and selectivity.Entities:
Keywords: E1 enzymes; adenosyl sulfamate inhibitors; cancer; drug design; ubiquitin; ubiquitin-activating enzyme; ubiquitin-like protein
Mesh:
Substances:
Year: 2017 PMID: 28578874 DOI: 10.1016/j.str.2017.05.001
Source DB: PubMed Journal: Structure ISSN: 0969-2126 Impact factor: 5.006